ASE · Medical - Instruments & Supplies
INFU (INFU) Stock
$9.92
+5.98%
ASE: INFU
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Are Investors Undervaluing InfuSystems Holdings (INFU) Right Now?
Zacks · Jun 29, 2026
InfuSystems Holdings (INFU) Soars 11.1%: Is Further Upside Left in the Stock?
Zacks · Jun 29, 2026
Should Value Investors Buy InfuSystems Holdings (INFU) Stock?
Zacks · Jun 12, 2026
Does InfuSystems Holdings (INFU) Have the Potential to Rally 62.61% as Wall Street Analysts Expect?
Zacks · Jun 5, 2026
Here is Why Growth Investors Should Buy InfuSystems Holdings (INFU) Now
Zacks · Jun 4, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held7.15%
Institutions Held79.13%
Institutions Float Held85.22%
Peer Comparison
About INFU
INFU is led by CEO Carrie A. Lachance, employs 502 people, headquartered in US, publicly traded since 2007.
INFU stock trades at $9.92 with a market capitalization of $200.20M. The stock is valued at a price-to-earnings (P/E) ratio of 32.90, price-to-book of 3.61, price-to-sales of 1.39. Over the past 52 weeks the stock has ranged between $5.38 and $11.04, and currently trades 10.1% below its 52-week high.
On profitability, INFU generates a return on equity (ROE) of 12.28%, above the typical market average, return on capital employed of 20.69%, an operating margin of 8.39%, a net profit margin of 5.56%.